GFP Reporter Cell Line - B16 BL6

MONCPT, a topoisomerase I inhibitor, has demonstrated potent antiproliferative and antiangiogenic activities in vitro and in vivo. Researchers evaluated the efficacy of MONCPT against melanoma metastasis. They found that MONCPT (2.0, 5.0, and 12.5 mg/kg/2 days) significantly reduced the occurrence of B16F10-GFP lung metastases by 12.8%, 53.1%, and 76.3%, respectively, by intravenously injecting B16F10 melanoma cells transfected with green fluorescent protein (B16F10-GFP) into C57BL/6 mice. In addition, a higher dose of MONCPT (31.0 mg/kg/2 days) significantly inhibited tumor growth in the B16F10 xenograft model. In in vitro experiments, MONCPT inhibited the invasion and migration of B16F10-GFP cells but did not affect cell survival. Further studies showed that MONCPT reduced the secretion of matrix metalloproteinase (MMP)-9 and VEGF, and decreased the protein expression of HIF-1α as well as the phosphorylation level of ERK in B16F10-GFP cells. These in vivo and in vitro results indicated that MONCPT not only possessed potent anti-metastatic ability, but also tumor growth inhibitory activity, showing the promise of MONCPT as a potential drug for the treatment of melanoma metastasis and tumor growth.

Figure 1. The researchers created and characterized a high-level GFP-expressing B16F10 cell line using pZsGreen-1 for stable expression and selection with G418. They compared cell doubling times and cell cycle distributions between B16F10-GFP and parental B16F10 cells, using flow cytometry to analyze the cell cycle. (Yang XC, et al., 2009)